PT705099E - Utilizacao do modafinil para o tratamento da apneia do sono e problemas respiratorios de origem central - Google Patents
Utilizacao do modafinil para o tratamento da apneia do sono e problemas respiratorios de origem central Download PDFInfo
- Publication number
- PT705099E PT705099E PT94919708T PT94919708T PT705099E PT 705099 E PT705099 E PT 705099E PT 94919708 T PT94919708 T PT 94919708T PT 94919708 T PT94919708 T PT 94919708T PT 705099 E PT705099 E PT 705099E
- Authority
- PT
- Portugal
- Prior art keywords
- modafinil
- treatment
- sleep
- sec
- central origin
- Prior art date
Links
- 238000011282 treatment Methods 0.000 title claims abstract description 17
- YFGHCGITMMYXAQ-UHFFFAOYSA-N 2-[(diphenylmethyl)sulfinyl]acetamide Chemical compound C=1C=CC=CC=1C(S(=O)CC(=O)N)C1=CC=CC=C1 YFGHCGITMMYXAQ-UHFFFAOYSA-N 0.000 title claims abstract description 16
- 229960001165 modafinil Drugs 0.000 title claims abstract description 16
- 230000000241 respiratory effect Effects 0.000 title description 5
- 201000002859 sleep apnea Diseases 0.000 claims abstract description 7
- 239000003814 drug Substances 0.000 claims description 6
- 230000000694 effects Effects 0.000 claims description 4
- 238000004519 manufacturing process Methods 0.000 claims description 4
- 239000003795 chemical substances by application Substances 0.000 claims description 2
- 208000023504 respiratory system disease Diseases 0.000 claims 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 208000035475 disorder Diseases 0.000 abstract 1
- 238000009423 ventilation Methods 0.000 abstract 1
- 208000008784 apnea Diseases 0.000 description 15
- 206010021079 Hypopnoea Diseases 0.000 description 2
- 206010041349 Somnolence Diseases 0.000 description 2
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 2
- 230000009286 beneficial effect Effects 0.000 description 2
- 210000003169 central nervous system Anatomy 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 230000000422 nocturnal effect Effects 0.000 description 2
- 239000001301 oxygen Substances 0.000 description 2
- 229910052760 oxygen Inorganic materials 0.000 description 2
- 230000000144 pharmacologic effect Effects 0.000 description 2
- 230000003860 sleep quality Effects 0.000 description 2
- 208000011580 syndromic disease Diseases 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 208000003417 Central Sleep Apnea Diseases 0.000 description 1
- 206010008120 Cerebral ischaemia Diseases 0.000 description 1
- 206010012289 Dementia Diseases 0.000 description 1
- 208000012661 Dyskinesia Diseases 0.000 description 1
- 102000001554 Hemoglobins Human genes 0.000 description 1
- 108010054147 Hemoglobins Proteins 0.000 description 1
- 208000018737 Parkinson disease Diseases 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 239000000935 antidepressant agent Substances 0.000 description 1
- 229940005513 antidepressants Drugs 0.000 description 1
- 206010003549 asthenia Diseases 0.000 description 1
- 230000036772 blood pressure Effects 0.000 description 1
- 208000020020 complex sleep apnea Diseases 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 230000003291 dopaminomimetic effect Effects 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 239000007789 gas Substances 0.000 description 1
- 201000006646 mixed sleep apnea Diseases 0.000 description 1
- PKIDMDXXGGEQEM-UHFFFAOYSA-N n-benzhydrylsulfinylacetamide Chemical compound C=1C=CC=CC=1C(S(=O)NC(=O)C)C1=CC=CC=C1 PKIDMDXXGGEQEM-UHFFFAOYSA-N 0.000 description 1
- 230000004770 neurodegeneration Effects 0.000 description 1
- 208000015122 neurodegenerative disease Diseases 0.000 description 1
- 239000003176 neuroleptic agent Substances 0.000 description 1
- 230000000701 neuroleptic effect Effects 0.000 description 1
- 230000000414 obstructive effect Effects 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 239000000523 sample Substances 0.000 description 1
- 230000004617 sleep duration Effects 0.000 description 1
- 239000000021 stimulant Substances 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
Landscapes
- Health & Medical Sciences (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pulmonology (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Electrotherapy Devices (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Orthopedics, Nursing, And Contraception (AREA)
- Control Of Throttle Valves Provided In The Intake System Or In The Exhaust System (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| FR9307555A FR2706767B1 (OSRAM) | 1993-06-22 | 1993-06-22 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PT705099E true PT705099E (pt) | 2002-03-28 |
Family
ID=9448411
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PT94919708T PT705099E (pt) | 1993-06-22 | 1994-06-14 | Utilizacao do modafinil para o tratamento da apneia do sono e problemas respiratorios de origem central |
Country Status (14)
| Country | Link |
|---|---|
| US (1) | US5612379A (OSRAM) |
| EP (1) | EP0705099B1 (OSRAM) |
| JP (1) | JP3703831B2 (OSRAM) |
| KR (1) | KR100315389B1 (OSRAM) |
| AT (1) | ATE207351T1 (OSRAM) |
| AU (1) | AU684087B2 (OSRAM) |
| CA (1) | CA2165824C (OSRAM) |
| DE (1) | DE69428791T2 (OSRAM) |
| DK (1) | DK0705099T3 (OSRAM) |
| ES (1) | ES2165878T3 (OSRAM) |
| FR (1) | FR2706767B1 (OSRAM) |
| HU (1) | HU216731B (OSRAM) |
| PT (1) | PT705099E (OSRAM) |
| WO (1) | WO1995000132A1 (OSRAM) |
Families Citing this family (33)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5618845A (en) * | 1994-10-06 | 1997-04-08 | Cephalon, Inc. | Acetamide derivative having defined particle size |
| US7160898B2 (en) * | 2001-12-14 | 2007-01-09 | Board Of Trustees Of The University Of Illinois | Pharmacological treatment for sleep apnea |
| US20060241164A1 (en) * | 1998-02-27 | 2006-10-26 | The Board Of Trustees Of The University Of Illinoi | Pharmacological treatment for sleep apnea |
| PT1066036E (pt) | 1998-02-27 | 2006-09-29 | Univ Illinois | Agentes com actividade relacionada com serotonina para o tratamento da apneia do sono |
| US6492396B2 (en) | 2000-05-16 | 2002-12-10 | Cephalon, Inc. | Substituted thioacetamides |
| BR0114814A (pt) * | 2000-10-11 | 2005-01-25 | Cephalon Inc | Composições compreendendo composto de modafinila e seu uso |
| MXPA03010705A (es) * | 2001-05-25 | 2004-05-27 | Cephalon Inc | Formulaciones farmaceuticas solidas que comprenden modafinil. |
| US20080058424A1 (en) * | 2002-05-23 | 2008-03-06 | Cephalon, Inc. | Novel pharmaceutical formulations of modafinil |
| US7229644B2 (en) * | 2002-05-23 | 2007-06-12 | Cephalon, Inc. | Pharmaceutical formulations of modafinil |
| US20040048931A1 (en) * | 2002-07-12 | 2004-03-11 | Craig Heacock | Modafinil pharmaceutical compositions |
| US6992219B2 (en) * | 2002-08-09 | 2006-01-31 | Cephalon France | Modafinil polymorphic forms |
| US20040116532A1 (en) | 2002-09-13 | 2004-06-17 | Craig Heacock | Pharmaceutical formulations of modafinil |
| IL153098A0 (en) * | 2002-11-26 | 2003-06-24 | Chemagis Ltd | Pharmaceutical compositions containing modafinil |
| US7528172B2 (en) * | 2003-01-21 | 2009-05-05 | The Cooper Health System, Inc. | Compositions and methods for improving recovery after general anesthesia |
| CA2519117C (en) * | 2003-03-17 | 2010-03-02 | Neurohealing Pharmaceuticals, Inc. | High potency dopaminergic treatment of neurological impairment associated with brain injury |
| US20040253308A1 (en) * | 2003-04-29 | 2004-12-16 | Barr Laboratories, Inc. | Surface-treated modafinil particles |
| AR045423A1 (es) * | 2003-05-13 | 2005-10-26 | Cephalon Inc | Combinaciones de analiticos y antidepresivos |
| US7368591B2 (en) | 2003-09-19 | 2008-05-06 | Cephalon France | Process for enantioselective synthesis of single enantiomers of modafinil by asymmetric oxidation |
| US7423176B2 (en) * | 2004-04-13 | 2008-09-09 | Cephalon, Inc. | Bicyclic aromatic sulfinyl derivatives |
| US7119214B2 (en) * | 2004-04-13 | 2006-10-10 | Cephalon France | Thio-substituted tricyclic and bicyclic aromatic methanesulfinyl derivatives |
| EP1586560A1 (en) * | 2004-04-13 | 2005-10-19 | Cephalon, Inc. | Thio-substituted arylmethanesulfinyl derivatives |
| US7449481B2 (en) * | 2004-04-13 | 2008-11-11 | Cephalon, Inc. | Thio-substituted biaryl-methanesulfinyl derivatives |
| US7297817B2 (en) * | 2004-04-13 | 2007-11-20 | Cephalon France | Thio-substituted arylmethanesulfinyl derivatives |
| US7314875B2 (en) * | 2004-04-13 | 2008-01-01 | Cephalon, Inc. | Tricyclic aromatic and bis-phenyl sulfinyl derivatives |
| CN101132777A (zh) * | 2004-12-20 | 2008-02-27 | 科利吉姆制药公司 | 用于睡眠障碍的药物组合物 |
| WO2007013962A2 (en) * | 2005-07-21 | 2007-02-01 | Neurohealing Pharmaceuticals, Inc. | Rapid onset and short term modafinil compositions and methods of use thereof |
| MX2009000391A (es) * | 2006-07-12 | 2009-06-30 | Elan Pharma Int Ltd | Formulación de modafinilo en forma de nano-partículas. |
| JP5395663B2 (ja) * | 2006-08-14 | 2014-01-22 | ニューロヒーリング・ファーマシューティカルズ・インコーポレーテッド | モダフィニルによる早漏の治療 |
| US20080181966A1 (en) * | 2006-10-18 | 2008-07-31 | Cephalon, Inc. | Modafinil pharmaceutical compositions |
| WO2008077127A2 (en) * | 2006-12-19 | 2008-06-26 | Lavin Thomas N | Use of modafinil to treat restless leg syndrome |
| CN102781446A (zh) * | 2010-01-07 | 2012-11-14 | 维瓦斯公司 | 采用碳酸酐酶抑制剂和另外的活性剂的组合治疗阻塞性睡眠呼吸暂停综合征 |
| WO2015030283A1 (ko) | 2013-08-30 | 2015-03-05 | 주식회사 녹십자에이치에스 | 진세노사이드 성분이 증가된 가공인삼분말 또는 가공인삼추출물을 함유하는 암 관련 피로의 예방 및 치료용 조성물 |
| US9616068B2 (en) | 2014-10-27 | 2017-04-11 | Pohela LLC | Animal training using cognitive enhancement |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB1584462A (en) * | 1977-03-31 | 1981-02-11 | Lafon Labor | N-diaryl-malonamide and diarylmethyl-sulphinyl-acetamide derivatives and pharmaceutical compositions containing them |
| FR2663225B1 (fr) * | 1990-06-14 | 1994-11-04 | Lafon Labor | Nouvelle utilisation du modafinil. |
| FR2684875B1 (fr) * | 1991-12-13 | 1995-05-24 | Lafon Labor | Utilisation du modafinil pour la fabrication d'un medicament ayant un effet anti-ischemique. |
| US5281607B1 (en) * | 1992-10-08 | 1998-05-19 | Univ New York | Method of using alpha 2-antagonists for the treatment of neurodegenerative diseases |
-
1993
- 1993-06-22 FR FR9307555A patent/FR2706767B1/fr not_active Expired - Fee Related
-
1994
- 1994-06-14 CA CA002165824A patent/CA2165824C/fr not_active Expired - Lifetime
- 1994-06-14 AT AT94919708T patent/ATE207351T1/de active
- 1994-06-14 US US08/564,286 patent/US5612379A/en not_active Expired - Lifetime
- 1994-06-14 KR KR1019950705833A patent/KR100315389B1/ko not_active Expired - Fee Related
- 1994-06-14 DE DE69428791T patent/DE69428791T2/de not_active Expired - Lifetime
- 1994-06-14 EP EP94919708A patent/EP0705099B1/fr not_active Expired - Lifetime
- 1994-06-14 AU AU70760/94A patent/AU684087B2/en not_active Expired
- 1994-06-14 PT PT94919708T patent/PT705099E/pt unknown
- 1994-06-14 ES ES94919708T patent/ES2165878T3/es not_active Expired - Lifetime
- 1994-06-14 JP JP50249895A patent/JP3703831B2/ja not_active Expired - Lifetime
- 1994-06-14 WO PCT/FR1994/000711 patent/WO1995000132A1/fr not_active Ceased
- 1994-06-14 HU HU9503702A patent/HU216731B/hu unknown
- 1994-06-14 DK DK94919708T patent/DK0705099T3/da active
Also Published As
| Publication number | Publication date |
|---|---|
| KR960703009A (ko) | 1996-06-19 |
| FR2706767A1 (OSRAM) | 1994-12-30 |
| US5612379A (en) | 1997-03-18 |
| ES2165878T3 (es) | 2002-04-01 |
| DE69428791D1 (de) | 2001-11-29 |
| JP3703831B2 (ja) | 2005-10-05 |
| EP0705099A1 (fr) | 1996-04-10 |
| CA2165824A1 (fr) | 1995-01-05 |
| DE69428791T2 (de) | 2002-07-04 |
| DK0705099T3 (da) | 2002-02-11 |
| AU7076094A (en) | 1995-01-17 |
| HUT74674A (en) | 1997-01-28 |
| WO1995000132A1 (fr) | 1995-01-05 |
| ATE207351T1 (de) | 2001-11-15 |
| HU9503702D0 (en) | 1996-02-28 |
| AU684087B2 (en) | 1997-12-04 |
| HU216731B (hu) | 1999-08-30 |
| EP0705099B1 (fr) | 2001-10-24 |
| KR100315389B1 (ko) | 2002-02-19 |
| CA2165824C (fr) | 2005-08-02 |
| JPH09500374A (ja) | 1997-01-14 |
| FR2706767B1 (OSRAM) | 1995-09-08 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PT705099E (pt) | Utilizacao do modafinil para o tratamento da apneia do sono e problemas respiratorios de origem central | |
| Taranto-Montemurro et al. | The combination of atomoxetine and oxybutynin greatly reduces obstructive sleep apnea severity. A randomized, placebo-controlled, double-blind crossover trial | |
| Strohl et al. | Progesterone administration and progressive sleep apneas | |
| Becker et al. | Reversal of sinus arrest and atrioventricular conduction block in patients with sleep apnea during nasal continuous positive airway pressure. | |
| Wu et al. | Low-dose dexmedetomidine improves sleep quality pattern in elderly patients after noncardiac surgery in the intensive care unit | |
| Villa et al. | Randomized controlled study of an oral jaw-positioning appliance for the treatment of obstructive sleep apnea in children with malocclusion | |
| Mamelak et al. | Treatment of narcolepsy and sleep apnea with gammahydroxybutyrate: a clinical and polysomnographic case study | |
| McEvoy et al. | Sleep apnoea in patients with quadriplegia. | |
| Guilleminault et al. | From apnea of infancy to obstructive sleep apnea syndrome in the young child | |
| Goff et al. | The cardiovascular response to arousal from sleep decreases with age in healthy adults | |
| Rollinson et al. | Postanoxic action myoclonus (Lance-Adams syndrome) responding to valproate | |
| Goold | Postoperative spasticity and shivering: a review with personal observations of 500 patients | |
| Dai et al. | Comparative evaluation of intravenous versus intranasal dexmedetomidine on emergence delirium and hemodynamics in pediatric patients undergoing adenotonsillectomy: a randomized controlled trial | |
| Padda et al. | Comparison of postoperative emesis, recovery profile, and analgesia in pediatric strabismus repair: rectal acetaminophen versus intravenous fentanyl-droperidol | |
| Steegers et al. | Propofol in total intravenous anaesthesia without nitrous oxide | |
| Samuels et al. | Difficulty reversing drug-induced coma in a patient with sleep apnea | |
| IL261984A (en) | Sultiame for the treatment of sleep apnea | |
| APPLETON et al. | A Neuroinhibitory Substance: Gamma Hydroxybutyric Acid preliminary report of first clinical trial in Britain | |
| Montgomery et al. | Marked suppression of ventilation while awake following massive ingestion of atenolol | |
| Cangemi Jr | Administration of general anesthesia for outpatient orthognathic surgical procedures | |
| Miller et al. | a preliminary report on THE USE OF INTRAMUSCULAR METHOHEXITAL SODIUM (BREVITAL®) FOR PEDIATRIC ANESTHESIA | |
| Searle et al. | Hemodynamic and pharmacodynamic comparison of doxacurium and high-dose vecuronium during coronary artery bypass surgery: a cost-benefit study | |
| Kim et al. | The influence of the amount of mandibular advancement in the application of mandibular advancement device for obstructive sleep apnea patients | |
| SINGH et al. | Efficiency of Magnesium Sulphate as a Sole Muscle Relaxant for General Anaesthesia with Vecuronium Bromide for Tracheal Intubation: A Prospective Interventional Study. | |
| Leoni et al. | Pain control with low-dose alfentanil in children undergoing minor abdominal and genito-urinary surgery |